Residency · Residency · Vascular Surgery

Anticoagulation Bridging and Perioperative Hemostasis

Introduction

Patients undergoing vascular surgery often require chronic anticoagulation or antiplatelet therapy due to underlying conditions such as atrial fibrillation, mechanical heart valves, venous thromboembolism, or previous vascular interventions. Managing antithrombotic therapy around the time of surgery involves carefully balancing the risk of thromboembolism that arises from stopping these medications against the increased risk of surgical bleeding if they are continued. This nuanced decision-making process is essential for ensuring safe outcomes in vascular surgical care.

Preoperative Assessment

Thrombotic Risk Stratification

Assessing thrombotic risk is a critical step in perioperative planning. Patients at high thrombotic risk include those with mechanical mitral valves, recent venous thromboembolism within the past three months, a CHA2DS2-VASc score of seven or greater, or a recent stroke. Those with moderate thrombotic risk typically have a bileaflet aortic mechanical valve accompanied by additional risk factors, a venous thromboembolism event occurring between three and twelve months prior, or a CHA2DS2-VASc score between five and six. Low thrombotic risk patients include those with a bileaflet aortic valve without other risk factors, venous thromboembolism that happened over a year ago, or a CHA2DS2-VASc score ranging from one to four.

Bleeding Risk Assessment

Bleeding risk is evaluated based on the type of surgical procedure and patient-specific factors. High bleeding risk procedures include open aortic surgery, major lower extremity bypass, and carotid endarterectomy. In contrast, low bleeding risk procedures encompass endovascular interventions with percutaneous access and arteriovenous fistula creation. Patient factors such as a history of prior bleeding events, thrombocytopenia, hepatic dysfunction, and concurrent use of antiplatelet agents also influence bleeding risk assessment.

Anticoagulant Management

Warfarin

Warfarin has a half-life of approximately 36 to 42 hours and is typically discontinued five days before surgery to allow the international normalized ratio (INR) to fall below 1.5. The INR should be checked on the day of surgery, and the procedure can proceed if the INR is less than 1.5. Warfarin is usually resumed 12 to 24 hours after surgery once hemostasis is confirmed. Bridging with heparin is indicated for patients at high thrombotic risk. This bridging can be achieved with low molecular weight heparin (LMWH), such as enoxaparin at 1 mg/kg twice daily, or with an unfractionated heparin (UFH) infusion. Bridging is initiated when the INR falls below 2.0, typically about three days before surgery. LMWH should be stopped 24 hours prior to surgery, while UFH is discontinued 4 to 6 hours before the procedure. Postoperatively, bridging anticoagulation is resumed 24 to 48 hours after surgery depending on the bleeding risk.

Direct Oral Anticoagulants (DOACs)

DOACs have a rapid onset and offset of action, which generally eliminates the need for bridging. Dabigatran should be stopped 2 to 3 days before high-risk procedures, extending to 5 days if the creatinine clearance is below 50 mL/min. Rivaroxaban, apixaban, and edoxaban are similarly discontinued 2 to 3 days before surgery. These agents are typically resumed 48 to 72 hours postoperatively in cases involving high bleeding risk.

Unfractionated Heparin

Intraoperative administration of unfractionated heparin, usually dosed at 80 to 100 units per kilogram, is standard practice during vascular clamping. The anticoagulant effect is monitored using the activated clotting time (ACT), with a target range of 200 to 300 seconds. Protamine sulfate is used for reversal at a dose of 1 mg per 100 units of heparin administered in the preceding 2 to 3 hours. However, protamine can cause adverse reactions such as hypotension, bradycardia, and rarely anaphylaxis, with increased risk in patients with fish allergies, prior protamine exposure, or those using NPH insulin.

Antiplatelet Therapy Management

Aspirin

Aspirin is generally continued for most vascular procedures because its benefit in maintaining vascular graft patency usually outweighs the risk of bleeding. However, aspirin may be held for 7 to 10 days before procedures that carry a high risk of bleeding in confined spaces, such as intracranial or spinal surgeries.

P2Y12 Inhibitors (Clopidogrel, Ticagrelor, Prasugrel)

Clopidogrel should be discontinued 5 to 7 days before surgery, ticagrelor 5 days prior, and prasugrel 7 to 10 days before the procedure. After coronary stent placement, elective surgery should be delayed for 30 days if a bare-metal stent was placed or for 6 months if a drug-eluting stent was used. Cardiologist consultation is advised for individualized decision-making in these cases.

Dual Antiplatelet Therapy (DAPT)

Premature discontinuation of dual antiplatelet therapy following coronary stenting carries a significant risk of stent thrombosis, ranging from 5% to 20%. For urgent vascular surgery in patients on DAPT, aspirin is continued while the P2Y12 inhibitor is held. Platelet transfusion may be considered if significant bleeding occurs. In selected cases, bridging with short-acting intravenous antiplatelet agents such as cangrelor can be employed.

Perioperative Hemostasis

Coagulation Monitoring

Coagulation status is monitored using several laboratory tests. The prothrombin time (PT) and INR assess warfarin effect and the extrinsic coagulation pathway. The activated partial thromboplastin time (aPTT) monitors heparin effect and the intrinsic pathway. The activated clotting time (ACT) is a point-of-care test used intraoperatively to monitor heparin anticoagulation. More comprehensive assessments of clot formation, strength, and fibrinolysis are provided by viscoelastic tests such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM), which are increasingly utilized in vascular surgery.

Blood Product Management

Transfusion thresholds guide blood product administration. Packed red blood cells are transfused when hemoglobin falls below 7 g/dL, or below 8 to 9 g/dL in patients with active coronary disease. Fresh frozen plasma is indicated for patients with an INR greater than 1.5 who have active bleeding, typically dosed at 10 to 15 mL/kg. Platelet transfusion is recommended when platelet counts are below 50,000 per microliter in the setting of active bleeding or prior to surgery. Cryoprecipitate is administered for fibrinogen levels less than 150 mg/dL, with each unit raising fibrinogen by approximately 5 to 10 mg/dL. Prothrombin complex concentrate (PCC) is preferred over fresh frozen plasma for rapid warfarin reversal in urgent or emergent surgery.

Reversal Agents

Specific reversal agents are available for various anticoagulants. Idarucizumab is used to reverse dabigatran with a 5 g intravenous dose. Andexanet alfa serves as the reversal agent for factor Xa inhibitors such as rivaroxaban and apixaban. Protamine reverses unfractionated heparin and partially reverses low molecular weight heparin. Vitamin K is used for warfarin reversal, with a 10 mg intravenous dose providing urgent reversal, although full effect may take 6 to 24 hours.

Key Clinical Pearls

Bridging anticoagulation should be reserved for patients at high thrombotic risk, as demonstrated by the BRIDGE trial, which showed no benefit and increased bleeding in patients with atrial fibrillation at moderate risk. Direct oral anticoagulants have predictable pharmacokinetics and generally do not require bridging; these agents can be held and resumed based on the bleeding risk associated with the procedure. Aspirin should be continued for most vascular surgeries to maintain graft and stent patency. Utilizing TEG or ROTEM to guide transfusion decisions reduces blood product use and improves hemostatic management. It is essential to have a clear plan for anticoagulation reversal before initiating surgery in anticoagulated patients.

References

1. Douketis JD, Spyropoulos AC, et al. "Perioperative bridging anticoagulation in patients with atrial fibrillation (BRIDGE trial)." N Engl J Med. 2015;373(9):823-833.
2. Defined, Defined, et al. "Perioperative management of antithrombotic therapy: ACCP guidelines." Chest. 2012;141(2 Suppl):e326S-e350S.
3. Defined, Defined, et al. "Direct oral anticoagulants: perioperative management." J Vasc Surg. 2018;68(5):1523-1533.
4. Defined, Defined, et al. "Viscoelastic testing in vascular surgery." J Vasc Surg. 2019;70(4):1324-1332.

Read this lecture as Markdown